Victoria Socha

DocwireNews

In May 2008, the Medical University of South Carolina, Charleston, dealt with the nationwide shortage of tacrolimus IR, requiring implementation of a de novo tacrolimus XR protocol. In a virtual presentation at the 2021 American Transplant Congress, N. Patel and colleagues at the center, reported on two different strategies of dosing tacrolimus XR in African American and non-African American de novo kidney transplant recipients. The presentation was titled Racial Differences in Tacrolimus XR Dosing in De Novo Kidney Transplant Recipients.The retrospective study included adult kidney transplant recipients between May 2020 and September 2020. The cohort was divided into two groups across two dosing strategies: non-African American and African American, and then further stratified based on initial dosing.&nbsp; The initial dosing strategy called for treating all patients between 0.12 mg/kg and 0.17 mg/kg tacrolimus XR, regardless of race. The second strategy called for treating non-African American patients with 0.12 mg/kg and African American patients with 0.15 mg/kg tacrolimus XR.The primary end point was days to a therapeutic tacrolimus trough (&gt;7 ng/mL). Other end points were dose at steady state, number of doses held, dose at post-operative day 30, time in therapeutic range in the first month, and adverse effects.The study included 122 patients: 57 in the African American group and 27 in the non-African American group. In the African American cohort, there was a statistically higher number of deceased donor kidney transplants and donation-after-cardiac death transplants. Recipients in the African American cohort also had significantly higher estimated post-transplant survival score, higher human leukocyte antigen mismatches, longer duration of dialysis, and were more likely to receive induction with anti-thymocyte globulin.In the initial analyses, there was a significant interaction between race and dosing strategy for the outcome of time to therapeutic level. During the initial dosing strategy, time to achieving a therapeutic trough was significantly longer among African Americans than among non-African Americans (6.2 days vs 4.4 days; P=.03). Also, during the initial dosing strategy, the incidence of neurotoxicity was significantly higher in the non-African American group than in the African American group.After the dosing strategy was changed for African American recipients, the time to a therapeutic level decreased to 4 days, with no significant difference between the two groups. The higher level of neurotoxicity in the non-African American recipients remained higher than in the African American recipients.&ldquo;The results demonstrate that African Americans can achieve a similar time to therapeutic tacrolimus trough concentrations with tacrolimus XR, as compared to non-African Americans, using a race stratified dosing strategy. Future analyses are underway to assess the impact of CYP 3A5 genotype on dose requirements and time to achieve therapeutic levels,&rdquo; the researchers said.Source: Patel N, Carcella T, Bartlett F, Rohan V, Taber D. Racial differences in tacrolimus XR dosing in de novo kidney transplant recipients. Abstract of a presentation at the virtual 2021 American Transplant Congress (Abstract #1273), June 5, 2021.

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Tacrolimus XR Dosing Strategies by Race

American Transplant Congress 2021

In May 2008, the Medical University of South Carolina, Charleston, dealt with the nationwide shortage of tacrolimus IR, requiring implementation of a de novo tacrolimus XR ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe